Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qol Holdings CoTSE:3034 +0.14%88 Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus rates TSE:3034 with a GF Score™ of 88/100 and a GF Value™ of 円2,284.03 (Fairly Valued). The stock has 1 warning sign investors should review. Among 580 Healthcare Providers & Services companies, Qol Holdings Co ranks better than 99.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Qol Holdings Co's annualized net income for the quarter that ended in Mar. 2026 was 円10,948 Mil. Qol Holdings Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円-11,993 Mil. Therefore, Qol Holdings Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was Negative Tangible Equity%.
The historical rank and industry rank for Qol Holdings Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:3034'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 28.15 Med: 64.78 Max: 160.45
Current: Negative Tangible Equity
During the past 13 years, Qol Holdings Co's highest Return-on-Tangible-Equity was 160.45%. The lowest was 28.15%. And the median was 64.78%.
TSE:3034's Return-on-Tangible-Equity is ranked better than 99.83% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.085
vs TSE:3034: Negative Tangible Equity
Qol Holdings Co (TSE:3034) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Qol Holdings Co Return-on-Tangible-Equity Related Terms
Qol Holdings Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Qol Holdings Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qol Holdings Co Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Qol Holdings Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qol Holdings Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Qol Holdings Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Qol Holdings Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Qol Holdings Co (TSE:3034) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qol Holdings Co and its competitors. Over the past decade, Qol Holdings Co's Return-on-Tangible-Equity has ranged from 28.15 to 160.45. According to the industry distribution chart, Qol Holdings Co ranks #1 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 0.2%.
Is Qol Holdings Co's Return-on-Tangible-Equity too high?
Qol Holdings Co's current Return-on-Tangible-Equity is Negative Tangible Equity%. Over the past 10 years, this metric has ranged from a low of 28.15 to a high of 160.45. Based on the distribution chart, Qol Holdings Co ranks #1 out of 580 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Qol Holdings Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Qol Holdings Co's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Qol Holdings Co ranks #1 out of 580 companies for Return-on-Tangible-Equity. This places Qol Holdings Co in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.09. Historically, Qol Holdings Co's own Return-on-Tangible-Equity has ranged from 28.15 to 160.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.09, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qol Holdings Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qol Holdings Co's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qol Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Qol Holdings Co (TSE:3034) is currently considered Fairly Valued. The stock's GF Value™ is 円2,284.03, compared to a current price of 円2,082.00 — trading 8.8% below its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Qol Holdings Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Qol Holdings Co (TSE:3034), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qol Holdings Co (TSE:3034) Overvalued in 2026?
Based on GuruFocus' analysis, Qol Holdings Co stock appears to be undervalued.
The current stock price of 円2,082.00 is trading 8.8% below its estimated GF Value™ of 円2,284.03.
GuruFocus considers Qol Holdings Co to be Fairly Valued.
No single metric tells the full story. See the TSE:3034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qol Holdings Co Ltd provides pharmacy services under health insurance and sells pharmaceutical products. Its mission is to create healthy and comfortable living environments for everybody in those communities. The company operates through: Pharmacy and BPO segments. Under the Pharmacy segment the company puts customers first in-store development strategy, which is based on building one-on-one relationships with drug-prescribing clinics and hospitals in order to get the pharmacy services that include medical information. The BPO contracting segment includes clinical trials and projects and develops pamphlets and websites for medical institutions to promote sales of pharmaceutical products and provide advice on proper pharmaceutical product.
88GF Score
Get the complete analysis for TSE:3034
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3034 has been successfully added to your 
